Dr. Shalini Thoutreddy, MD

Dr. Thoutreddy practices at McLaren Oakland in Pontiac, Michigan, part of McLaren Health Care.

Dr. Thoutreddy's NPI, 1831197581, was assigned on July 7, 2005. Dr. Thoutreddy holds Michigan license 4301080565.

Dr. Thoutreddy's primary practice is McLaren Oakland, at 50 N Perry St, Pontiac, MI 48342 in Oakland County. The practice phone is (248) 338-5000.

Dr. Thoutreddy's primary practice is McLaren Oakland in Pontiac, Michigan, part of McLaren Health Care. Dr. Thoutreddy is also affiliated with McLaren Flint. The medical group on file is McLaren Oakland. Dmand AI also links Dr. Thoutreddy to 2 more hospitals, 1 group practice or clinic, 1 skilled nursing facility and 1 medical group, each named with a free account. Dr. Thoutreddy's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Thoutreddy practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Thoutreddy's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Thoutreddy is licensed in Michigan.

CMS data shows 1,487 Medicare services from Dr. Thoutreddy across 10 procedure codes in 2024, for 416 Medicare patients. Medicare paid $120,022 for them.

CMS counts 416 Medicare patients who saw Dr. Thoutreddy in 2024. The largest group is 65 to 74, with 160 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Thoutreddy's median patient age at 74, with 59% women.

In 2024, Dr. Thoutreddy wrote 1,488 Medicare Part D claims for 252 patients. 78% of them were for generic drugs. CMS names the drug for 1,212 of them, across 31 drugs with 11 or more claims each, at $1,973,628 in total drug cost. In 2023, CMS named 1,037 claims across 26 drugs.

Dr. Thoutreddy accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Thoutreddy to 2 clinical trials, 2 of them phase 1 studies. Conditions studied include Adenocarcinoma, Bronchiolo-Alveolar, Ovarian Neoplasms and Adenocarcinoma of Lung. Barbara Ann Karmanos Cancer Institute sponsors the most, 2.

CMS Open Payments shows 43 general payments to Dr. Thoutreddy from 16 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 90% of the total. Bristol-Myers Squibb Company paid the most, $208.